1443038-07-0

Basic information

• Product Name: [2-chloro-6-fluoro-4-(4-fluoro-benzoyl)-phenoxy]acetic acid hydrazide
• Synonyms: [2-chloro-6-fluoro-4-(4-fluoro-benzoyl)-phenoxy]acetic acid hydrazide
• CAS NO: 1443038-07-0
• Molecular Weight: 340.714
• Mol File: 1443038-07-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: [2-chloro-6-fluoro-4-(4-fluoro-benzoyl)-phenoxy]acetic acid hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: [2-chloro-6-fluoro-4-(4-fluoro-benzoyl)-phenoxy]acetic acid hydrazide(1443038-07-0)
• EPA Substance Registry System: [2-chloro-6-fluoro-4-(4-fluoro-benzoyl)-phenoxy]acetic acid hydrazide(1443038-07-0)

Safety Data

• Hazardous Substances Data: 1443038-07-0(Hazardous Substances Data)

Upstream product

• 2040-90-6 2-chloro-6-fluorophenol 
• 403-43-0 4-fluorobenzoyl chloride 
• 1443038-02-5 [4-(4-fluorobenzoyl)-2-chloro-6-fluorophenoxy]ethanoic acid 
• 1443037-97-5 ethyl [2-(4-fluorobenzoyl)-2-chloro-6-fluorophenoxy]acetate 
• 1443037-92-0 (3-chloro-5-fluoro-4-hydroxyphenyl)-4-fluorophenyl methanone 
• 1443037-87-3 2-chloro-6-fluorophenyl-4-fluorobenzoate 

Downstream Products

• 1443038-12-7 N,N-di[di(2-chloro-6-fluoro-4-(4-fluoro-benzoyl)phenoxy)]acetyl hydrazide 
• 1443038-22-9 2,5-di[2-fluoro-4-(4-fluoro)benzoyl-6-chlorophenoxymethyl]-1,3,4-oxadiazole 

Relevant articles and documents

The critical role of novel benzophenone analogs on tumor growth inhibition targeting angiogenesis and apoptosis

In modern biology, one of the major topics of importance is progress in anti-cancer drugs with specific targets. The angiopreventive and in vitro tumor inhibition activities of novel synthetic benzophenone analogs have been investigated intensively and explored in a very systematic way. Novel benzophenone analogs (9a-d and 10a-d) substituted with methyl, chloro and fluoro groups at different positions on an identical chemical backbone and incorporating variations in the number of substituents have been synthesized in a multistep process and characterized. In this study, we further evaluate the newly synthesized compounds for their cytotoxic and anti-proliferative effects against A549, HeLa and MCF-7 cells. The potent lead compound was further assessed for anti-angiogenic effects. Through the structure-activity relationship, we found that an increase in the number of methyl, chloro and fluoro groups in a benzophenone ring on compound 9d resulted in higher potency compared to other compounds. Tumor inhibition was notably promoted, and this was reflected in effects on neovessel formation in in vivo systems, such as the CAM. Compound 9d interacts with rVEGF through hydrogen bonds in silico, thereby down-regulating the expression of VEGF in angiogenesis. From our investigation, it is suggested on the basis of clonogenesis and cell migration assays that compound 9d has the potency to exhibit prolonged activity against cancer progression, through cell cycle arrest at the G2/M phase. In addition, compound 9d inhibits A549 cells through caspase-activated DNase-mediated apoptosis.

Synthesis and evaluation of 2,5-di(4-aryloylaryloxymethyl)-1,3,4- oxadiazoles as anti-cancer agents

A series of 2,5-di(4-aryloylaryloxymethyl)-1,3,4-oxadiazoles 9a-j were obtained via multistep synthesis from hydroxybenzophenones 4a-e. The cytotoxicity of compounds 9a-j was evaluated against human leukemia cell lines (K562 and CEM). The compounds exhibited moderate to good anti-cancer activity with compounds 9b and 9i having a chloro group exhibiting the best activity (IC50 = 10 μM). Compound 9i exhibited activity against both the cell lines and 9b only exhibited activity against CEM. Further, a lactate dehydrogenase (LDH) assay and DNA fragmentation studies of the compounds 9a-j were also performed.